Library
MD-Prolintan
MD-prolintane is the 3,4-methylenedioxy analogue of prolintane and structurally the de-ketone counterpart of MDPV. Users describe functional, cocaine-like stimulation with reduced peripheral tension compared to alpha-PVP. Duration is approximately 4-6 hours with reports of smoother comedowns than related pyrrolidinophenones. High oral bioavailability is reported; insufflation increases potency but causes nasal irritation. Use accurate scales for dosing as the compound is dense.
Also known as: Methylenedioxyprolintane
Classification
- Psychoactive: Stimulant
- Tag: Pyrrolidine
- Tag: Research-Chemical
Effects
- Stimulation
- Increased Heart Rate
- Vasoconstriction
- Insomnia
- Jaw Tension
- Loss Of Appetite
- Focus Enhancement
- Motivation Enhancement
- Cognitive Euphoria
- Wakefulness
- Thought Acceleration
- Time Distortion
- Increased Libido
- Appetite Suppression
- Light Sensitivity
- Disinhibition
- Dehydration
- Tactile Enhancement
Routes of Administration
Oral
Dosage
- Threshold: 2 mg
- Light: 5-10 mg
- Common: 10-25 mg
- Strong: 25-40 mg
- Heavy: 40 mg
Duration
- Onset: 0.33-0.67 h
- Comeup: 0.5-1 h
- Peak: 1-3 h
- Offset: 1-2 h
- After Effects: 2-12 h
Insufflated
Dosage
- Threshold: 2 mg
- Light: 5-15 mg
- Common: 15-30 mg
- Strong: 30-50 mg
- Heavy: 50 mg
Duration
- Onset: 0.08-0.17 h
- Comeup: 0.17-0.33 h
- Peak: 1-3 h
- Offset: 1-2 h
- After Effects: 2-12 h
Vaporized / Smoked
Dosage
- Threshold: 2 mg
- Light: 5-10 mg
- Common: 10-25 mg
- Strong: 25-40 mg
- Heavy: 40 mg
Duration
- Onset: 0.03 h
- Comeup: 0.08-0.17 h
- Peak: 1-3 h
- Offset: 1-2 h
- After Effects: 2-12 h
Intravenous
Dosage
- Threshold: 1 mg
- Light: 1-5 mg
- Common: 5-15 mg
- Strong: 15-25 mg
- Heavy: 25 mg
Duration
- Onset: 0.02 h
- Comeup: 0.02-0.08 h
- Peak: 1-3 h
- Offset: 1-2 h
- After Effects: 2-12 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
Links
This static page is intended as a readable non-JS and prerender-friendly library export.
